British pharmaceutical giant GlaxoSmithKline PLC has spent more than $3.2 billion over the past five years on research and acquisitions specifically related to an anticipated flu pandemic. Now comes the payoff as the swine flu sweeps the world. Law Professor Kevin Outterson, head of the Health Law Program and an authority on drug marketing, said Glaxo deserves what it now can reap.
“It is very important for governments to reward Glaxo for these efforts. We should stop insisting on bargain prices for valuable vaccines produced to address pandemics.”
Contact Kevin Outterson, 617-353-3103, email@example.com